Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

June 9, 2011

Men May Be at Greater Risk Than Women for Developing HPV-Related Cancers

Author(s):

Jon Garinn

HPV-positive oral cancers are on the rise.

A new analysis from the National Cancer Institute suggests that the number of HPV-positive oral cancers among men could rise significantly in the next decade, possibly surpassing HPV-positive cervical cancers among women.

The genital human papillomavirus (HPV) is the most common sexually transmitted infection in the U.S., according to the Centers for Disease Control and Prevention. About 20 million Americans are currently infected and about 6 million are infected each year.

Using population-based cancer registry data, the researchers found that between 1988 and 2004, oropharyngeal cancers related to HPV increased by 225 percent, with men accounting for the majority of cases. Relying on U.S. Census projections and age-period-cohort models, they projected a 27 percent rise in cases by 2020.

More than 40 types of HPV are spread during genital, oral or anal sex with an infected partner—some are low-risk (wart-causing) while others are high-risk (cancer-causing). In most cases, the body's own immune system gets rid of HPV within about two years of infection. But if the body cannot clear the infection, it can develop into several cancers, including oropharyngeal and cervical, which is the second leading cause of cancer deaths in women worldwide.

Gardasil, the only approved vaccine for young men and women, is effective against two types of cancer-causing HPV and two types of wart-causing HPV. Cervarix is an HPV vaccine approved only for women.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of bald man.
Image of man with black hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Dr. Michael Moore
Dr. Michael Moore
Dr. Michael Moore
Related Content
Advertisement
Keytruda was approved for locally advanced head and neck cancer before and after surgery: © stock.adobe.com.
June 12th 2025

FDA Approves Perioperative Keytruda for Locally Advanced Head and Neck Cancer

Spencer Feldman
Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Image of neck.
May 23rd 2025

GLP-1 Drugs Linked to Fewer Obesity-Related Cancers

Ariana Pelosci
GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Illustration of neck.
April 25th 2025

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

Alex Biese
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma: © stock.adobe.com.
April 24th 2025

FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma

Alex Biese
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.
Related Content
Advertisement
Keytruda was approved for locally advanced head and neck cancer before and after surgery: © stock.adobe.com.
June 12th 2025

FDA Approves Perioperative Keytruda for Locally Advanced Head and Neck Cancer

Spencer Feldman
Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Image of neck.
May 23rd 2025

GLP-1 Drugs Linked to Fewer Obesity-Related Cancers

Ariana Pelosci
GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Illustration of neck.
April 25th 2025

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

Alex Biese
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma: © stock.adobe.com.
April 24th 2025

FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma

Alex Biese
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.